Vietnam Ministry of Health and Quintiles collaborate to advance clinical trial excellence
The Vietnam Ministry of Health’s Administration of Science, Technology and Training (ASTT) has signed an agreement with Quintiles (NYSE: Q) to enhance clinical research in this growing nation of 90 million people, Quintiles, world’s largest provider of biopharmaceutical development and commercial outsourcing services, has revealed.
This collaboration marks a new stage in the Ministry’s efforts to support the development of new, better therapies for diseases that afflict the populations of Vietnam and Southeast Asia, said ASTT Director Nguyen Cong Khan.
“Quintiles knows how to conduct clinical research to global standards and its experts understand Asia and Vietnam. By sharing their knowledge and insights, Quintiles can help us develop and execute a long-term plan for improving the quality, scope and breadth of clinical research in Vietnam,” said Prof Khan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze